Per A. Peterson, MD, PhD recently retired as Chairman, Research and Development, Pharmaceuticals, at Johnson & Johnson. He joined J&J in 1994 as Vice President, Drug Discovery, of the R.W. Johnson Pharmaceutical Research Institute, and was named President of the group in 1998. In 2000, he was named Chairman, R&D Pharmaceuticals Group and became a Member of the Executive Committee in 2001. Prior to joining J&J Dr. Peterson spent eight years at Scripps Research Institute in La Jolla, California, where he headed the Division of Molecular Immunogenetics before being appointed Chairman of the Department of Immunology in 1987. He had previously served as Director of the Wallenberg Laboratory, as well as professor of cell biology at the University of Uppsala, Sweden. Born in Kalmar, Sweden, Dr. Peterson received his B.M. in Medicine and his PhD in medicinal biochemistry from the University of Uppsala, Sweden.
Frederick Frank currently holds several biotechnology corporate board positions including PDL Biopharma and Biotech Investment Group. Mr. Frank is Vice Chairman of the Peter J. Solomon Company, and was Vice Chairman of Barclays Capital. Prior to that, he held the positions of Vice Chairman and Director at Lehman Brothers, which was acquired by Barclays in September 2008 and which he joined as a Partner in October 1969. Before coming to Lehman, Mr. Frank was Co-Director of Research and Vice President and Director of Smith, Barney & Co. Mr. Frank is a director of Landec Corporation, a publicly-traded company, a member of the advisory boards of the Pharmaceutical Executive Magazine and the Journal of Life Sciences, past Chairman of the Board of the Irvington Institute for Immunological Research and formerly served on the Advisory Board of The Harvard School of Public Health, the Johns Hopkins Bloomberg School of Public Health and the Massachusetts Institute of Technology Center for Biomedical Innovation. Mr. Frank serves on the Yale School of Management Advisory Board, and holds a B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
Lee E. Babiss, PhD is a member of the board of advisory of Biotech Investment Group (B.I.G.), and an EVP of Global Laboratory Services at Pharmaceutical Product Development Inc. since February 2010. Dr. Babiss provides strategic direction and additional scientific leadership to Pharmaceutical Product Development’s bioanalytical, cGMP and global central laboratories, vaccines and biologics operations and to BioDuro, a B.I.G. company, which was acquired by PPD last year. He served as Head of Global Pharma Research at Roche Holding AG since July 1, 2007. Dr. Babiss also served as Vice President of Preclinical Research and Development at Roche Holding AG until July 1, 2007. He was responsible for developing and directing oncology, metabolic diseases, and inflammation research strategy at Roche Holding AG. Dr. Babiss also serves as a member of the International Research Management Team, involved in developing global research strategy, and chairs the Roche Biomarker Leadership Team, a cross-divisional effort within pharmaceuticals and diagnostics focused on the development and implementation of Roche Holding AG’s biomarker strategy. Prior to Roche, he served as Vice President of Biological Sciences and Genetics at Glaxo Wellcome. He has more than 21 years of experience developing and leading research and development laboratories. Dr. Babiss served as President and Director of pharmaceutical research for F. Hoffmann-La Roche, Ltd., in Basel, Switzerland. His responsibilities included leading global laboratory functions in chemistry, discovery technologies, therapeutic proteins, RNA-based therapeutics, non-clinical safety, technical sciences and informatics. Dr. Babiss has received numerous fellowship awards and grants and serves on several scientific advisory committees and boards. He attended graduate school at Columbia University, College of Physicians and Surgeons, in New York, where Dr. Babiss received a PhD in Microbiology in 1982 studying DNA tumor viruses.
Jay M. Short, PhD is an advisor to Biotech Investment Group, and currently serves Chairman and CEO of BioAtla, a B.I.G. portfolio company. He is also a founder of Diversa Corporation (now Verenium) where he served through 2005 in multiple roles including CEO, President, Chief Technology Officer, and Director for the company. Before joining Diversa Corporation, Dr. Short served as President of Stratacyte, Inc., the first company to express libraries of antibodies in bacteria, and Vice President of Research & Development and Operations for Stratagene Cloning Systems, a molecular biology company based in La Jolla, California. Dr. Short earned his MD in Biochemistry at Case Western Reserve University and his BA in chemistry with honors at Taylor University. Dr. Short received San Diego’s 2001 Ernst & Young Entrepreneur of the Year Award in Health Sciences and was the recipient of two first place awards granted by UCSD’s Connect Innovative Product Program. Dr. Short has served on numerous boards including Invitrogen (now Life Technologies), Senomyx, Femta Pharmaceuticals, BioDuro, E.O. Wilson Biodiversity Foundation, and Ciris Energy.